Bayer Sales Surprise on Demand for New Cancer, Kidney Drugs
- Annual pharma sales guidance raised as Eylea outperforms
- North American demand helps crop science unit beat estimates
The pharma division is facing competition for blockbuster medicines Xarelto, a blood thinner.
Photographer: Scott Olson/Getty Images
This article is for subscribers only.
Bayer AG reported encouraging sales for the quarter aided by strong demand for new cancer and kidney medicines.
Group revenue reached €11.1 billion ($12.2 billion) in the second quarter, the German company said in a statement Tuesday, ahead of the €10.9 billion average of analysts’ estimates. Bayer reiterated its 2024 earnings forecast.